382 related articles for article (PubMed ID: 26976583)
1. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.
Harriman G; Greenwood J; Bhat S; Huang X; Wang R; Paul D; Tong L; Saha AK; Westlin WF; Kapeller R; Harwood HJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1796-805. PubMed ID: 26976583
[TBL] [Abstract][Full Text] [Related]
2. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals.
Harwood HJ; Petras SF; Shelly LD; Zaccaro LM; Perry DA; Makowski MR; Hargrove DM; Martin KA; Tracey WR; Chapman JG; Magee WP; Dalvie DK; Soliman VF; Martin WH; Mularski CJ; Eisenbeis SA
J Biol Chem; 2003 Sep; 278(39):37099-111. PubMed ID: 12842871
[TBL] [Abstract][Full Text] [Related]
3. Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.
Bengtsson C; Blaho S; Saitton DB; Brickmann K; Broddefalk J; Davidsson O; Drmota T; Folmer R; Hallberg K; Hallén S; Hovland R; Isin E; Johannesson P; Kull B; Larsson LO; Löfgren L; Nilsson KE; Noeske T; Oakes N; Plowright AT; Schnecke V; Ståhlberg P; Sörme P; Wan H; Wellner E; Oster L
Bioorg Med Chem; 2011 May; 19(10):3039-53. PubMed ID: 21515056
[TBL] [Abstract][Full Text] [Related]
4. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
5. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Kim CW; Addy C; Kusunoki J; Anderson NN; Deja S; Fu X; Burgess SC; Li C; Ruddy M; Chakravarthy M; Previs S; Milstein S; Fitzgerald K; Kelley DE; Horton JD
Cell Metab; 2017 Aug; 26(2):394-406.e6. PubMed ID: 28768177
[TBL] [Abstract][Full Text] [Related]
6. Acetyl-CoA carboxylase 2 inhibition reduces skeletal muscle bioactive lipid content and attenuates progression of type 2 diabetes in Zucker diabetic fatty rats.
Takagi H; Ikehara T; Hashimoto K; Tanimoto K; Shimazaki A; Kashiwagi Y; Sakamoto S; Yukioka H
Eur J Pharmacol; 2021 Nov; 910():174451. PubMed ID: 34454928
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models.
Svensson RU; Parker SJ; Eichner LJ; Kolar MJ; Wallace M; Brun SN; Lombardo PS; Van Nostrand JL; Hutchins A; Vera L; Gerken L; Greenwood J; Bhat S; Harriman G; Westlin WF; Harwood HJ; Saghatelian A; Kapeller R; Metallo CM; Shaw RJ
Nat Med; 2016 Oct; 22(10):1108-1119. PubMed ID: 27643638
[TBL] [Abstract][Full Text] [Related]
8. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.
Savage DB; Choi CS; Samuel VT; Liu ZX; Zhang D; Wang A; Zhang XM; Cline GW; Yu XX; Geisler JG; Bhanot S; Monia BP; Shulman GI
J Clin Invest; 2006 Mar; 116(3):817-24. PubMed ID: 16485039
[TBL] [Abstract][Full Text] [Related]
9. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
[TBL] [Abstract][Full Text] [Related]
10. Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome.
Harwood HJ
Curr Opin Investig Drugs; 2004 Mar; 5(3):283-9. PubMed ID: 15083594
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of mammalian acetyl-CoA carboxylase.
Corbett JW; Harwood JH
Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):162-80. PubMed ID: 18221116
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anti-cancer activity of ND-646 and its derivatives as acetyl-CoA carboxylase 1 inhibitors.
Li EQ; Zhao W; Zhang C; Qin LZ; Liu SJ; Feng ZQ; Wen X; Chen CP
Eur J Pharm Sci; 2019 Sep; 137():105010. PubMed ID: 31325544
[TBL] [Abstract][Full Text] [Related]
13. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
[TBL] [Abstract][Full Text] [Related]
14. Acetyl-CoA carboxylases 1 and 2 show distinct expression patterns in rats and humans and alterations in obesity and diabetes.
Kreuz S; Schoelch C; Thomas L; Rist W; Rippmann JF; Neubauer H
Diabetes Metab Res Rev; 2009 Sep; 25(6):577-86. PubMed ID: 19618481
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, Biological Evaluation and Molecular Docking Studies of Piperidinylpiperidines and Spirochromanones Possessing Quinoline Moieties as Acetyl-CoA Carboxylase Inhibitors.
Huang T; Sun J; Wang Q; Gao J; Liu Y
Molecules; 2015 Sep; 20(9):16221-34. PubMed ID: 26370948
[TBL] [Abstract][Full Text] [Related]
16. FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.
Mottillo EP; Desjardins EM; Fritzen AM; Zou VZ; Crane JD; Yabut JM; Kiens B; Erion DM; Lanba A; Granneman JG; Talukdar S; Steinberg GR
Mol Metab; 2017 Jun; 6(6):471-481. PubMed ID: 28580278
[TBL] [Abstract][Full Text] [Related]
17. A Novel Acetyl-CoA Carboxylase 2 Selective Inhibitor Improves Whole-Body Insulin Resistance and Hyperglycemia in Diabetic Mice through Target-Dependent Pathways.
Takagi H; Tanimoto K; Shimazaki A; Tonomura Y; Momosaki S; Sakamoto S; Abe K; Notoya M; Yukioka H
J Pharmacol Exp Ther; 2020 Mar; 372(3):256-263. PubMed ID: 31900320
[TBL] [Abstract][Full Text] [Related]
18. Changes in hepatic lipogenic and oxidative enzymes and glucose homeostasis induced by an acetyl-L-carnitine and nicotinamide treatment in dyslipidaemic insulin-resistant rats.
Ferreira MR; Camberos Mdel C; Selenscig D; Martucci LC; Chicco A; Lombardo YB; Cresto JC
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):205-11. PubMed ID: 23278446
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of fat oxidation, but no sustained reduction of hepatic lipids by prolonged pharmacological inhibition of acetyl CoA carboxylase.
Glien M; Haschke G; Schroeter K; Pfenninger A; Zoller G; Keil S; Müller M; Herling AW; Schmoll D
Horm Metab Res; 2011 Aug; 43(9):601-6. PubMed ID: 21823054
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel spiro-pentacylamides as acetyl-CoA carboxylase inhibitors.
Wei Q; Mei L; Yang Y; Ma H; Chen H; Zhang H; Zhou J
Bioorg Med Chem; 2018 Aug; 26(14):3866-3874. PubMed ID: 30049586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
